Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

July 7, 2020

Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021
ONS-5010 / LYTENAVA™
Bay Street News

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search